Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) have gained 46.2% in the past six months against the industry's decline of 2%.
The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters.
The company is also making good progress with its promising set of pipeline candidates.
Factors Driving CORT Stock in the Given Time Frame
Corcept has made steady progress with the development of its lead pipeline candidate, relacorilant, which is being evaluated in the phase III GRACE study for the treatment of Cushing's syndrome, also known as hypercortisolism.
Image Source: Zacks Investment Research
The GRACE study comprises two parts — the open-label portion and the randomized withdrawal phase. In May 2024, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study's primary endpoint, versus placebo.
In April, the company announced data from the open-label phase of the GRACE study, which showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia, as well as other symptoms.
Per ...
